血浆循环DNA在肺癌诊断上的应用

Evaluation of plasma circulating tumor DNA in early diagnosis non-small cell lung cancer

目的研究血浆循环Fhit基因D3S1300位点杂合性缺失(LOH)作为肿瘤标志物在非小细胞肺癌早期诊断中的意义。方法以微卫星技术检测58例非小细胞肺癌(Nonsmallcelllungcancer,NSCLC)患者血浆及肿瘤组织以及40例非肺癌肺科住院患者血浆Fhit基因D3S1300LOH的表达情况。结果58例NSCLC患者中肿瘤组织D3S1300LOH检出率为41.4%(24/58),在其匹配的血浆中D3S1300LOH检出率为29.3%(17/58),二者差异有统计学意义(P<0.05)。对照组血浆游离DNAD3S1300LOH检出率为5%(2/40),与NSCLC组比较差异有统计学意义(P<0.01)。结论血浆循环DNAFhit基因D3S1300LOH是一种简单有效的肺癌肿瘤筛选标志物。

Objective To investigate the loss of heterozygosity（LOH） of D3S1300 in Fhit gene of plasma circulating DNA as tumor marker in early diagnosis of non-small cell lung cancer （NSCLC） . Methods Microsatellite analysis was performed by using the primer of D3S1300 in plasma and cancinoma tissues from 58 patients with primary NSCLC, and in plasma of 40 control subjects. Results D3S1300 LOH ratios detected in the tumor tissue and plasma DNA of patients with NSCLC were 41.4% and 29.3% , respectively. In contrast, there was only 5% LOH ratio in plasma of control group （ P 〈 0.01, vs NSCLC group）. Conclusion Fhit gene D3S1300 LOH in plasma circulating DNA can be used as a tranor marker in diagnosis is of lung cancer.